CXL-1020 是一种基于羟胺基的硝基 (HNO) 供体。CXL-1020 改善舒张异常大鼠的心肌收缩性/舒张性和 Ca2+循环。CXL-1020 在犬模型中诱导血管舒张，改善心脏功能。CXL-1020 已被用于研究收缩期心力衰竭和稳定期心力衰竭。
| 生物活性 | CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca2+cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure[1]. |
| IC50& Target[1] | |
体内研究
(In Vivo) | CXL-1020 (100 μg/kg/min; infusion for 30 min) improves hemodynamics and cardiac function, and enhances both diastolic and systolic performance in mice[1].
CXL-1020 (3 and 10 mg/kg/min; 4-hour intravenous infusion) improves left ventricular systolic and diastolic function in dogs with advanced heart failure[2].
| Animal Model: | Adult male Sprague-Dawley rats (250-350 g; induced cardiac dysfunction by isoproterenol)[1] | | Dosage: | 100 μg/kg/min | | Administration: | For 30 min | | Result: | Improved hemodynamics and cardiac function in normal rats, and enhanced both diastolic and systolic performance in cardiac dysfunction mice. |
| Animal Model: | Dogs (coronary microembolization-induced heart failure)[2]3 and 10 mg/kg/min | | Dosage: | 3 and 10 mg/kg/min | | Administration: | 4-hour intravenous infusion | | Result: | Decreased systolic aortic pressure (AoP) modestly; significantly increased EF and deceleration time of early mitral inflow velocity (DT) and significantly lowered left ventricular (LV) end-systolic volume (ESV), LV end-diastolic pressure (EDP) and end-diastolic wall stress (EDWS) in a dose-dependent manner. |
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com